News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,823 Results
Type
Article (40014)
Company Profile (250)
Press Release (664558)
Multimedia
Podcasts (58)
Webinars (14)
Section
Business (204275)
Career Advice (2011)
Deals (35454)
Drug Delivery (95)
Drug Development (81146)
Employer Resources (172)
FDA (16250)
Job Trends (14887)
News (345504)
Policy (32607)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49570)
ALS (108)
Alzheimer's disease (1440)
Antibody-drug conjugate (ADC) (151)
Approvals (16246)
Artificial intelligence (308)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11637)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (364)
Cancer (2855)
Cardiovascular disease (212)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (497)
Cervical cancer (22)
Clinical research (66849)
Collaboration (1011)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2624)
CRISPR (56)
C-suite (324)
Cystic fibrosis (112)
Data (2991)
Decentralized trials (2)
Denatured (20)
Depression (60)
Diabetes (346)
Diagnostics (6423)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (137)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87445)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113735)
Executive appointments (845)
FDA (17892)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (928)
Gene editing (129)
Generative AI (22)
Gene therapy (372)
GLP-1 (780)
Government (4500)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (148)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3636)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (491)
Leadership (18)
Legal (7929)
Liver cancer (79)
Longevity (3)
Lung cancer (399)
Lymphoma (208)
Machine learning (11)
Management (58)
Manufacturing (383)
MASH (90)
Medical device (13460)
Medtech (13465)
Mergers & acquisitions (19577)
Metabolic disorders (847)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2115)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (427)
Opinion (217)
Ovarian cancer (101)
Pain (105)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (296)
Patient recruitment (163)
Peanut (50)
People (57681)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20829)
Phase II (29444)
Phase III (21920)
Pipeline (1626)
Policy (198)
Postmarket research (2563)
Preclinical (8869)
Press Release (64)
Prostate cancer (139)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (457)
Real estate (5917)
Recruiting (66)
Regulatory (22626)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (156)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (36)
Vaccines (778)
Venture capital (53)
Weight loss (256)
Women's health (47)
Worklife (16)
Date
Today (66)
Last 7 days (366)
Last 30 days (1866)
Last 365 days (31222)
2025 (16714)
2024 (35219)
2023 (40076)
2022 (51174)
2021 (55711)
2020 (54083)
2019 (46540)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38204)
Australia (6232)
California (7426)
Canada (2355)
China (669)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82101)
Florida (1115)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (361)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1019)
Massachusetts (5516)
Michigan (246)
Minnesota (449)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2070)
New Mexico (28)
New York (2082)
North Carolina (1078)
North Dakota (8)
Northern California (3269)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1609)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2777)
Tennessee (126)
Texas (1120)
United States (27509)
Utah (219)
Virginia (184)
Washington D.C. (72)
Washington State (630)
West Virginia (4)
Wisconsin (66)
704,823 Results for "chemocentryx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI).
October 20, 2022
·
14 min read
Deals
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
August 4, 2022
·
16 min read
Business
ChemoCentryx Announces Changes to its Board of Directors
ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.
May 31, 2022
·
4 min read
Business
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022.
July 5, 2022
·
4 min read
Business
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET.
August 9, 2022
·
7 min read
Biotech Bay
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan).
May 31, 2022
·
8 min read
Press Releases
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
July 15, 2025
·
13 min read
Business
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022.
August 2, 2022
·
2 min read
Business
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
ChemoCentryx, Inc., announced financial results for the first quarter ended March 31, 2022 and provided an overview of recent corporate highlights.
May 5, 2022
·
16 min read
Biotech Bay
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November.
October 17, 2022
·
10 min read
1 of 70,483
Next
